We are pioneers of silicon-based Bio-Courier® technology, an advanced and highly tailored approach that advances drug delivery into the age of precision medicine. Built upon a decade of research and patented technological innovation, our platform is changing the way therapeutic molecules target disease helping to make tomorrow’s medicines a reality.
SiSaf is a commercial stage biopharmaceutical company. Our pipeline of transformative Gene Therapies, accelerated New Therapeutic Entities and advanced Personal Care development candidates create multiple blockbuster opportunities.
Led by an authority in the delivery of nucleic acid and silicon innovation, Dr Suzanne Saffie-Siebert, our expert team is focused on driving clinical and commercial success.
SiSaf’s Bio-Courier platform leverages the unique properties of the worlds 1st bioabsorbable silicon (14Si) to overcome the limitations of current drug technologies.
We’re creating multiple block-buster product opportunities with the safe and efficient non-viral delivery of gene therapy and a faster, lower risk approach to drug development.
Non-invasive ocular siRNA delivery induces effective gene silencing in corneal epitheliumMore
SiSaf announces licencing agreement to develop gene therapy for rare bone diseaseMore
SiSaf Makes Its Bio-Courier® Technology Available for COVID-19 Vaccine ResearchMore
SiSaf Establishes Strategic Partnership with Avellino LabsMore
SiSaf Strengthens it’s Leadership TeamMore
SiSaf Ltd Appoints Former Oxford BioMedica ExecutiveMore
Croda Invests in SiSaf’s Novel Bio-Courier TechnologyMore
UK based biopharmaceutical company SiSaf closes $4.3 million interim funding roundMore
SiSaf’s Chairwoman and Chief Executive Officer, Suzanne Saffie-Siebert featured on BBC Radio 4’s ‘In Business’More
Next-gen silicon nanotechnology drug delivery company SiSaf raises $3.5 million in Series A FundingMore
Silicon Valley Investors Lead Funding Round in SiSafMore
SiSaf Releases latest Clinical Data Showing a 95% Reduction in AcneMore